Overview
- This week the team published a peer‑reviewed study in the Journal of Experimental Medicine showing CASS4 acts in microglia to surround and compact toxic amyloid‑beta plaques.
- In 5xFAD mouse models, full‑body loss of Cass4 left microglia unable to form dense plaque barriers, which increased plaque spread, caused neuronal injury, and worsened cognition.
- Phosphoproteomic profiling of purified microglia revealed that Cass4 deletion disrupts focal‑adhesion signaling, a cell‑movement and attachment pathway needed for microglial plaque containment.
- UVA researchers are now screening small molecules and testing gene‑therapy vectors to boost or mimic CASS4 in human microglia and are evaluating defective CASS4 as a possible early biomarker.
- The work is preclinical, NIH/NIA and foundation funded, the authors report no financial conflicts, and clinical benefit will require showing safety and effectiveness in human cells and trials.